Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The peptide market has exploded with options and with that growth has come a wide range of quality, transparency, and marketing claims that can make it genuinely difficult to figure out what you're actually getting
This isnt a magic wand
Pharmacokinetic Notes: Short-acting GLP-1 RAs (exenatide BID, lixisenatide) primarily affect postprandial glucose and tend to cause more gastrointestinal side effects initially due to rapid high peaks
SURMOUNT-1 (Jastreboff 2022, NEJM) reported up to 20.9 percent average weight loss with tirzepatide versus 14.9 percent with semaglutide in STEP 1 (Wilding 2021, NEJM)
Sende provides personalized treatment plans that combine the latest medical advances with comprehensive lifestyle optimization.
